Bristol Myers: FDA approves Abecma in multiple myeloma

(CercleFinance.com) - Bristol Myers Squibb and its partner 2seventy bio announce that the US Food and Drug Administration (FDA) has approved Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy comprising an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody.


This approval extends Abecma's indication, making it available earlier to patients who have relapsed or become refractory after exposure to these three main classes of treatment (triple-class exposure), after two prior lines of treatment.

Abecma has demonstrated three times the progression-free survival benefit of standard treatment regimens for relapsed or refractory multiple myeloma, and we are now bringing the promise of cell therapy to patients earlier in their treatment journey, it said.


Copyright (c) 2024 CercleFinance.com. All rights reserved.